(CRSP) Crispr Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0334081137

Gene Editing, CAR-T, Hemoglobinopathies, Diabetes, Oncology

Stock: Biotechnology
Age 9.3y
MCap 5,100m
Avg Vol 1.53M (85.6M USD)
Beta 1.277
Volatility 71.57%

EPS (Earnings per Share)

EPS (Earnings per Share) of CRSP over the last years for every Quarter: "2020-12": -1.5, "2021-03": -1.51, "2021-06": 9.44, "2021-09": -1.67, "2021-12": -1.84, "2022-03": -2.32, "2022-06": -2.4, "2022-09": -2.24, "2022-12": -1.41, "2023-03": -0.67, "2023-06": -0.98, "2023-09": -1.41, "2023-12": 1.1, "2024-03": -1.43, "2024-06": -1.49, "2024-09": -1.01, "2024-12": -0.44, "2025-03": -1.58, "2025-06": -1.29, "2025-09": -1.17, "2025-12": 0,
EPS CAGR: 93.08%
EPS Trend: 37.8%
Last SUE: 2.46
Qual. Beats: 1

Revenue

Revenue of CRSP over the last years for every Quarter: 2020-12: 0.37, 2021-03: 0.202, 2021-06: 900.202, 2021-09: 0.329, 2021-12: 12.899, 2022-03: 0.178, 2022-06: 0.158, 2022-09: 0.094, 2022-12: 0.006, 2023-03: 100, 2023-06: 70, 2023-09: 0, 2023-12: 200, 2024-03: 0.504, 2024-06: 0.517, 2024-09: 0.602, 2024-12: 35, 2025-03: 0.865, 2025-06: 0.892, 2025-09: 0.889, 2025-12: null,
Rev. CAGR: -51.00%
Rev. Trend: -3.8%
Last SUE: -0.27
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 71.6%
Value at Risk 5%th 104%
Relative Tail Risk -11.81%
Reward TTM
Sharpe Ratio 0.60
Alpha 7.61
CAGR/Max DD 0.03
Character TTM
Hurst Exponent 0.487
Beta 1.277
Beta Downside 0.781
Drawdowns 3y
Max DD 64.91%
Mean DD 32.39%
Median DD 36.07%

Description: CRSP Crispr Therapeutics January 09, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based biotech that leverages its CRISPR/Cas9 platform to develop gene-edited medicines for high-unmet-need diseases, spanning hemoglobinopathies, oncology (CAR-T), in-vivo editing, and type-1 diabetes.

Its lead candidate, **CASGEVY**, is an ex-vivo edited hematopoietic stem-cell therapy designed to reactivate fetal hemoglobin, aiming for transfusion independence in beta-thalassemia and sickle-cell disease. Recent Phase 3 data (reported Q2 2024) showed >90 % of treated patients achieving transfusion-free status, a key efficacy milestone.

Beyond CASGEVY, the pipeline includes CAR-T programs such as **CTX112** (CD19) and **CTX131** (CD70), in-vivo editors **CTX310/CTX320** targeting ANGPTL3 and Lp(a) for cardiovascular risk reduction, and **CTX211**, an allogeneic, hypo-immune stem-cell product for type-1 diabetes. Strategic alliances with Vertex, Nkarta, and Capsida provide co-development funding and shared IP.

Financially, CRISPR reported cash and cash equivalents of **$1.2 billion** at the end of Q3 2024, giving it roughly 18 months of runway at current burn (~$70 million per quarter). The broader CRISPR therapeutics market is projected to grow at a **CAGR of ~20 %** through 2030, driven by accelerating regulatory approvals and expanding indications.

For a deeper dive into CRSP’s valuation metrics and risk-adjusted upside, the ValueRay platform offers a concise analyst toolkit.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -488.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA -5.03 > 1.0
NWC/Revenue: 4808 % < 20% (prev 919.6%; Δ 3889 % < -1%)
CFO/TA -0.13 > 3% & CFO -302.5m > Net Income -488.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 16.22 > 1.5 & < 3
Outstanding Shares: last quarter (91.3m) vs 12m ago 7.12% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.67% > 50% (prev 8.94%; Δ -7.26% > 0%)
Interest Coverage Ratio: -8.62 > 6 (EBITDA TTM -529.5m / Interest Expense TTM -63.6m)

Altman Z'' -4.75

A: 0.81 (Total Current Assets 1.93b - Total Current Liabilities 119.0m) / Total Assets 2.25b
B: -0.81 (Retained Earnings -1.82b / Total Assets 2.25b)
C: -0.24 (EBIT TTM -548.2m / Avg Total Assets 2.25b)
D: -5.49 (Book Value of Equity -1.81b / Total Liabilities 329.3m)
Altman-Z'' Score: -4.75= D

Beneish M -3.24

DSRI: 0.67 (Receivables 25.0m/200.0m, Revenue 37.6m/201.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 2.23 (AQ_t 0.03 / AQ_t-1 0.01)
SGI: 0.19 (Revenue 37.6m / 201.6m)
TATA: -0.08 (NI -488.3m - CFO -302.5m) / TA 2.25b)
Beneish M-Score: -3.24 = AA

ValueRay F-Score (Strict, 0-100) 29.63

1. Piotroski: 0.0pt
2. FCF Yield: -8.93%
3. FCF Margin: data missing
4. Debt/Equity: 0.11
5. Debt/Ebitda: data missing
6. ROIC - WACC: -33.91%
7. RoE: -26.44%
8. Revenue Trend: -3.81%
9. EPS Trend: 37.77%

What is the price of CRSP shares?

As of January 26, 2026, the stock is trading at USD 55.52 with a total of 2,392,844 shares traded.
Over the past week, the price has changed by +3.76%, over one month by -1.66%, over three months by -17.39% and over the past year by +25.53%.

Is CRSP a buy, sell or hold?

Crispr Therapeutics has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy CRSP.
  • Strong Buy: 12
  • Buy: 5
  • Hold: 10
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the CRSP price?

Issuer Target Up/Down from current
Wallstreet Target Price 83.5 50.3%
Analysts Target Price 83.5 50.3%
ValueRay Target Price 57 2.6%

CRSP Fundamental Data Overview January 18, 2026

P/E Forward = 23.3645
P/S = 133.0181
P/B = 2.6616
P/EG = -0.2142
Revenue TTM = 37.6m USD
EBIT TTM = -548.2m USD
EBITDA TTM = -529.5m USD
Long Term Debt = 211.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 211.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.5m USD (from netDebt column, last quarter)
Enterprise Value = 3.39b USD (5.10b + Debt 211.0m - CCE 1.92b)
Interest Coverage Ratio = -8.62 (Ebit TTM -548.2m / Interest Expense TTM -63.6m)
EV/FCF = -11.20x (Enterprise Value 3.39b / FCF TTM -303.1m)
FCF Yield = -8.93% (FCF TTM -303.1m / Enterprise Value 3.39b)
FCF Margin = -805.2% (FCF TTM -303.1m / Revenue TTM 37.6m)
Net Margin = -1297 % (Net Income TTM -488.3m / Revenue TTM 37.6m)
Gross Margin = -355.6% ((Revenue TTM 37.6m - Cost of Revenue TTM 171.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.51 (Enterprise Value 3.39b / Total Assets 2.25b)
Interest Expense / Debt = 8.43% (Interest Expense 17.8m / Debt 211.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -433.0m (EBIT -548.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.22 (Total Current Assets 1.93b / Total Current Liabilities 119.0m)
Debt / Equity = 0.11 (Debt 211.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -75.5m / EBITDA -529.5m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -75.5m / FCF TTM -303.1m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.70% (Net Income -488.3m / Total Assets 2.25b)
RoE = -26.44% (Net Income TTM -488.3m / Total Stockholder Equity 1.85b)
RoCE = -26.63% (EBIT -548.2m / Capital Employed (Equity 1.85b + L.T.Debt 211.0m))
RoIC = -23.44% (negative operating profit) (NOPAT -433.0m / Invested Capital 1.85b)
WACC = 10.46% (E(5.10b)/V(5.31b) * Re(10.62%) + D(211.0m)/V(5.31b) * Rd(8.43%) * (1-Tc(0.21)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.77%
Fair Price DCF = unknown (Cash Flow -303.1m)
EPS Correlation: 37.77 | EPS CAGR: 93.08% | SUE: 2.46 | # QB: 1
Revenue Correlation: -3.81 | Revenue CAGR: -51.00% | SUE: -0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.09 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-4.46 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+27.9% | Growth Revenue=+1964.1%

Additional Sources for CRSP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle